Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Stephen R. Bertenshaw is active.

Publication


Featured researches published by Stephen R. Bertenshaw.


Bioorganic & Medicinal Chemistry Letters | 1996

Conformationally restricted 1,5-diarylpyrazoles are selective COX-2 inhibitors

Stephen R. Bertenshaw; John J. Talley; Donald J. Rogier; Matthew J. Graneto; Carol M. Koboldt; Yan Zhang

Abstract Benzothiopyranopyrazoles and benzopyranopyrazoles containing either a sulfone or sulfonamide moiety were synthesized and tested for COX-1 and COX-2 inhibition. This new class of COX-2 selective inhibitors possess antiinflammatory activity in vivo.


Bioorganic & Medicinal Chemistry Letters | 1995

3,4-diarylthiophenes are selective COX-2 inhibitors

Stephen R. Bertenshaw; John J. Talley; Donald J. Rogier; Matthew J. Graneto; Roland S. Rogers; Steven W. Kramer; Thomas D. Penning; Carol M. Koboldt; Amy W. Veenhuizen; Yan Zhang; William E. Perkins

Abstract A group of 3,4-diarylthiophenes containing either a sulfone or sulfonamide moiety were synthesized and tested for COX-1 and COX-2 inhibition. They are selective inhibitors of COX-2 and possess antiinflammatory activity in vivo .


Medicinal Research Reviews | 1999

4,5‐Diaryloxazole inhibitors of cyclooxygenase‐2 (COX‐2)

John J. Talley; Stephen R. Bertenshaw; David L. Brown; Jeffery S. Carter; Mathew J. Graneto; Carol M. Koboldt; Jaime L. Masferrer; Bryan H. Norman; D. Joseph Rogier; Ben S. Zweifel; Karen Seibert

A series of methysulfonyl or sulfonamido substituted 4,5‐diaryloxazole were prepared and evaluated for their ability to inhibit the inducible form of cyclooxygenase (COX‐2) in vitro and in vivo. Several unique substitution patterns were identified that led to potent and selective inhibitors of COX‐2. In general, 2‐trifluoromethly‐4,5‐diaryloxazoles substituted with a methylsulfonyl or sulfonamido group were particularly potent inhibitors. One of the more potent compounds with a selectivity for COX‐2 of about 800 fold was 4b (SC‐299). SC‐299, a highly fluorescent molecule, may be useful for spectroscopic studies on preferential inhibitor binding to COX‐2.


Journal of Medicinal Chemistry | 1997

Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)

Thomas D. Penning; John J. Talley; Stephen R. Bertenshaw; Jeffery S. Carter; Paul W. Collins; Stephen H Docter; Matthew J. Graneto; Len F. Lee; James W. Malecha; Julie M. Miyashiro; Roland S. Rogers; Donald J. Rogier; Stella S. Yu; Gary D. Anderson; Earl G. Burton; J. Nita Cogburn; Susan A. Gregory; Carol M. Koboldt; William Perkins; Karen Seibert; Amy W. Veenhuizen; and Yan Y. Zhang; Peter C. Isakson


Archive | 1993

Substituted pyrazolyl benzenesulfonamides

John J. Talley; Thomas D. Penning; Paul W. Collins; Donald J. Rogier; James W. Malecha; Julie M. Miyashiro; Stephen R. Bertenshaw; Ish K. Khanna; Matthew J. Graneto; Roland S. Rogers; Jeffery S. Carter


Archive | 1994

Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation

John J. Talley; Thomas D. Penning; Paul W. Collins; Donald J. Rogier; James W. Malecha; Julie M. Miyashiro; Stephen R. Bertenshaw; Ish K. Khanna; Matthew J. Graneto; Roland S. Rogers; Jeffery S. Carter; Stephen H Docter; Stella S. Yu


Archive | 1998

Prodrugs of benzenesulfonamide-containing COX-2 inhibitors

John J. Talley; James W. Malecha; Stephen R. Bertenshaw; Matthew J. Graneto; Jeffery S. Carter; Jinglin Li; Srinivasan Nagarajan; David L. Brown; Donald J. Rogier; Thomas D. Penning; Ish K. Khanna; Xiangdong Xu; Richard M. Weier


Archive | 1998

Substituted benzopyran derivatives for the treatment of inflammation

Jeffery S. Carter; Mark G. Obukowicz; Balekudru Devadas; John J. Talley; David L. Brown; Matthew J. Graneto; Stephen R. Bertenshaw; Donald J. Rogier; Srinivasan Nagarajan; Cathleen E Hanau; Susan J. Hartmann; Cindy L Ludwig; Suzanne Metz


Archive | 1994

Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents

John J. Talley; Stephen R. Bertenshaw; Paul W. Collins; Thomas D. Penning; David B. Reitz; Roland S. Rogers


Archive | 1999

Substituted benzopyran analogs for the treatment of inflammation

Jeffery S. Carter; Mark G. Obukowicz; Balekudru Devadas; John J. Talley; David L. Brown; Matthew J. Graneto; Stephen R. Bertenshaw; Donald J. Rogier; Srinivasan Nagarajan; Cathleen E Hanau; Susan J. Hartmann; Cindy L Ludwig; Suzanne Metz; Donald E. Korte

Collaboration


Dive into the Stephen R. Bertenshaw's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge